IC-OS Weekly Webinar - Between a Rock and a Heart Place: Arrhythmias in Targeted Therapies

Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Dr. Moore is originally from eastern North Carolina. She completed her undergraduate degree in biology at North Carolina State University and received her doctorate of pharmacy at the UNC Eshelman School of Pharmacy in Chapel Hill. She completed her general residency training at the Durham Veterans Affairs Hospital where she realized her passion for oncology and then continued on to complete oncology residency training at VCU hospital in Richmond, Virginia. After residency, she decided to return home to North Carolina and accepted a position in the breast oncology clinic at the Duke Cancer Institute. She has developed a specific interest in cardio oncology given the cardiotoxicity seen with many breast cancer therapies which led to involvement within the cardio oncology program at Duke. In her free time, she enjoys reading, playing tennis, supporting NC State athletics and spending time with her dog, Chauncey.

Olivia White is originally from Auburn, AL. She received her Bachelor of Science in Biology from the College of Charleston and her Doctor of Pharmacy degree from the University of Kentucky. Her practice interests include oncology and transplant. In addition to her clinical responsibilities, Dr. White serves on the oncology formulary evaluation team and is working towards earning her teaching and learning certificate. This year, her research will evaluate Isavuconazonium vs. Posaconazole for antifungal prophylaxis in patients with Acute Myeloid Leukemia. Upon completion of her PGY1 pharmacy residency, she plans to pursue a second year of residency training in one of her clinical interest areas. In the future, she hopes to obtain board certification, practice at an academic medical center, and become involved in the development of students and residents. Outside of pharmacy, she enjoys cooking and exploring new restaurants!